Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatm ...

AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...

BAT2206 is a proposed biosimilar to Jansen's Stelara®. Bio-Thera has filed for regulatory approval of BAT2206 with the China ...

A Russian cargo ship sank in the Mediterranean Sea between Spain and Algeria, leaving two crew members missing, Spain’s maritime rescue agency and the Russian Foreign Ministry ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) withdraw EU marketing application for lung cancer therapy Dato-DXd. Read more ...

Quality compliance in the pharma industry is foundational to guaranteeing safe and effective products. For years, Good ...

Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not ...

Catch up on all the latest pharma industry news from the past month, from breakthroughs in gene therapy to promising drug ...

European stocks edged higher in cautious trade on Tuesday ahead of Christmas break. The German DAX is not trading today while the ...

(Alliance News) - AstraZeneca PLC and its Japanese partner Daiichi-Sankyo Co Ltd have withdrawn an application in the European Union for datopotamab deruxtecan for treating certain forms of non-small ...

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management.